Summary
Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on November 4, 2015, to report its financial and operating results for the third quarter ended September 30, 2015. The press release detailing these results is furnished as an exhibit to the filing, providing investors with timely information on the company's performance during the period. The filing indicates that while specific financial figures are not detailed within the 8-K itself, the accompanying press release contains the comprehensive results, including revenue, earnings, and other operational metrics. Investors should refer to the press release (Exhibit 99.1) for detailed insights into Regeneron's third-quarter performance. This includes information crucial for assessing the company's growth trajectory, profitability, and the overall health of its business. The disclosure is standard for earnings announcements and allows the market to react to the company's latest financial standing and operational developments.
Key Highlights
- 1Regeneron announced its third-quarter 2015 financial and operating results on November 4, 2015, via an 8-K filing.
- 2The press release containing the Q3 2015 results is furnished as Exhibit 99.1 to the 8-K.
- 3The 8-K filing itself does not contain detailed financial figures, directing investors to the press release for specifics.
- 4The filing is for the period ended September 30, 2015.
- 5This disclosure is routine for reporting quarterly earnings and operational performance.
- 6Information furnished under Item 2.02 is generally not considered 'filed' for purposes of Section 18 of the Exchange Act, unless specifically incorporated into other filings.